Latest Commercial Growth News

Oneview Healthcare reported robust commercial growth in 2025, driven by new US client wins and the launch of its AI-powered care assistant, Ovie. The company enters 2026 with a confident outlook focused on expanding its US footprint and advancing digital health innovation.

Adherium Limited has reached a pivotal commercial milestone by expanding its Remote Patient Monitoring program across 110 U.S. Allergy Partners clinics, activating nearly 70% of the network and onboarding close to 700 patients in six months.

First Graphene Limited has raised A$3.5 million through a share placement to accelerate the commercial adoption of its PureGRAPH graphene products and support ongoing operations.

InteliCare successfully completed its largest aged care pilot at mecwacare’s Trescowthick Centre and secured $2 million in funding, while navigating a key leadership transition.

Acrux Limited reports robust revenue growth in Q1 FY26, driven by strong profit share income from recently launched topical pharmaceuticals and a significant R&D tax rebate repayment.

Alexium International Group reported a 26% rise in Q1 FY26 sales driven by new business wins and expanded foam bedding applications, while navigating tighter funding conditions.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

Singular Health Group has advanced its US expansion through the deployment of 3DICOM™ licenses under a key contract with Provider Network Solutions, alongside appointing a new US commercial chief to drive growth.

Botanix Pharmaceuticals reports a strong start to FY26 with a 50% surge in Sofdra prescriptions and a 65% rise in net revenue, underpinned by a larger sales team and operational efficiencies.

ImpediMed secures expanded insurance reimbursement for its SOZO platform, now covering over 301 million US lives and enhancing early detection of breast cancer-related lymphedema.

Papyrus Australia has appointed Daniel Schmidt as CEO and secured a $250k government grant alongside a binding agreement to produce biodegradable mining products, marking a decisive shift from R&D to commercial operations.

Aquirian Limited reports a 16.7% revenue increase alongside key operational advances at its Wubin facility and new leadership appointments, signaling strong momentum in mining services and technology.